FDA Should "Raise The Bar" For NDA Supplement Exclusivity, Teva Says
Executive Summary
FDA should maintain higher standards for awarding exclusivity for NDA supplements to prevent abuse of the Waxman-Hatch amendments by innovator firms, Teva maintained in comments on FDA's draft guidance on discontinued labeling.